Kyriaki Liadaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kyriaki Liadaki has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Anastasios E. Germenis
Department of Immunology and Histocompatibility, School of Medicine, University of Thessaly, Larissa, Greece
1 shared publication - Apostolos Zaravinos
Department of Life Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus; Cancer Genetics, Genomics and Systems Biology Laboratory, Basic and Translational Cancer Research Center (BTCRC), Nicosia, Cyprus
1 shared publication Göran Carlsson
Department of Women's and Children's Health (KBH), Karolinska University Hospital Solna, 17176 Stockholm, Sweden
1 shared publicationJacek Winiarski
Division of Pediatrics (CLINTEC), Karolinska Institutet at Karolinska University Hospital Huddinge, SE-14186 Stockholm, Sweden
1 shared publication- Johanna Lundin
Department of Molecular Medicine and Surgery and Center for Molecular Medicine, Karolinska Institutet, SE-17176, Stockholm, Sweden; Department of Clinical Genetics, Karolinska University Hospital, SE-17176, Stockholm, Sweden
1 shared publication Konstantinos Gourgoulianis
Respiratory Medicine Department, University of Thessaly Medical School, 41110 Larissa, Greece
1 shared publication
Latest Publications
- 1 March 2017
- Published by Elsevier in Clinical Immunology
- Vol. 176, 71-76
NEIL1 is a candidate gene associated with common variable immunodeficiency in a patient with a chromosome 15q24 deletion
- 1 March 2017
- Published by Elsevier in Clinical Immunology
- Vol. 176, 71-76
NEIL1 is a candidate gene associated with common variable immunodeficiency in a patient with a chromosome 15q24 deletion
- Open Access
- 1 January 2009
- Published by Wiley in Journal of Immunology Research
- Vol. 2009, 1-6
Association of TLR4-T399I Polymorphism with Chronic Obstructive Pulmonary Disease in Smokers
Tobacco smoking has been considered the most important risk factor for chronic obstructive pulmonary disease (COPD) development. However, not all smokers develop COPD and other environmental and genetic susceptibility factors underlie disease pathogenesis. Recent studies have indicated that the impairment of TLR signaling might play a crucial role in the development of emphysema. For this purpose we investigated the prevalence and any possible associations of common TLR polymorphisms (-R753Q, -D299G, and -T399I) in a group of 240 heavy smokers (>20 pack years), without overt atherosclerosis disease, of whom 136 had developed COPD and 104 had not. The presence of -T399I polymorphism was associated with a 2.4-fold increased risk for COPD development (), but not with disease stage or frequency of exacerbations. Considering that infections contribute to COPD and emphysema pathogenesis, our findings possibly indicate that dysfunctional polymorphisms of innate immune genes can affect the development of COPD in smokers. Although this finding warrants further investigation, it highlights the importance of impaired innate immunity towards COPD development.
- 1 January 2009
- Published by Wiley in Journal of Immunology Research
- Vol. 2009, 1-6
Open AccessAssociation of TLR4-T399I Polymorphism with Chronic Obstructive Pulmonary Disease in Smokers
Tobacco smoking has been considered the most important risk factor for chronic obstructive pulmonary disease (COPD) development. However, not all smokers develop COPD and other environmental and genetic susceptibility factors underlie disease pathogenesis. Recent studies have indicated that the impairment of TLR signaling might play a crucial role in the development of emphysema. For this purpose we investigated the prevalence and any possible associations of common TLR polymorphisms (-R753Q, -D299G, and -T399I) in a group of 240 heavy smokers (>20 pack years), without overt atherosclerosis disease, of whom 136 had developed COPD and 104 had not. The presence of -T399I polymorphism was associated with a 2.4-fold increased risk for COPD development (), but not with disease stage or frequency of exacerbations. Considering that infections contribute to COPD and emphysema pathogenesis, our findings possibly indicate that dysfunctional polymorphisms of innate immune genes can affect the development of COPD in smokers. Although this finding warrants further investigation, it highlights the importance of impaired innate immunity towards COPD development.